* Molecular weight (daltons) 330.7 * % Bioavailability 47-70% * Bioavailability with end-stage renal disease 43 - 46% * % Protein binding 91–99 * Volume of distribution (L/kg) 0.07 – 0.2 * Volume of distribution may be higher in patients with cirrhosis or nephrotic syndrome * Excretion * % Excreted in urine (% of total dose) 60 - 90 * % Excreted unchanged in urine (% of total dose) 53.1 - 58.8 * % Excreted in feces (% of total dose) 7 - 9 * % Excreted in bile (% of total dose) 6 - 9 * Approximately 10% is metabolized by the liver in healthy individuals, but this percentage may be greater in individuals with severe kidney failure * Renal clearance (mL/min/kg) 2.0 * Elimination half-life (hrs) 2 * Prolonged in congestive heart failure (mean 3.4 hrs) * Prolonged in severe kidney failure (4 - 6 hrs) and anephric patients (1.5-9 hrs) * Time to peak concentration (hrs) * Intravenous administration 0.3 * Oral solution 0.83 * Oral tablet 1.45 The pharmacokinetics of<unk>  are apparently not significantly altered by food. No direct relationship has been found between<unk>  concentration in the plasma and<unk>  efficacy. Efficacy depends upon the concentration of<unk>  in urine.
Furosemide
Amiloride
Bumetanide
Chlorothiazide
Cyclothiazide
Spironolactone
Torasemide
Tolvaptan